Payment overview · 2025
General Payments
$1,081.05
70 reported records · 13 companies
Healthcare provider profile · identity verified
Tracy Sizemore, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MANCHESTER, KY · NPI 1184015042
Verified facts
What the public records show
CMS Open Payments records show Tracy Sizemore, APRN received $1,081.05 in general payments during 2025 across 70 reported records.
ABBVIE INC. accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $235.73 | 21.8% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $182.87 | 16.9% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $148.99 | 13.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $127.96 | 11.8% | 13 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $85.63 | 7.9% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $82.52 | 7.6% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.98 | 4.7% | 8 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $45.13 | 4.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $40.16 | 3.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.81 | 2.8% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.61 | 1.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.92 | 1.7% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $14.74 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,081.05 | 70 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $168.03 | 11 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $152.64 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $136.11 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $135.18 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $97.94 | 10 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $97.94 | 10 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $85.63 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $82.52 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $51.55 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $51.55 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $50.98 | 8 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $45.13 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $40.16 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $31.54 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $31.54 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $30.02 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $29.81 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $29.81 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $14.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 108 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 71 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 69 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
108 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
71 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
79 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 878 | 92 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 632 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 379 | 70 |
| Atorvastatin Calcium | Atorvastatin Calcium | 374 | 73 |
| Lisinopril | Lisinopril | 362 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 309 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 285 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 285 | 51 |
| Tramadol Hcl | Tramadol Hcl | 279 | 40 |
| Levothyroxine Sodium | Levothyroxine Sodium | 235 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 222 | 36 |
| Famotidine | Famotidine | 208 | 34 |
| Clonazepam | Clonazepam | 206 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 172 | 36 |
| Omeprazole | Omeprazole | 169 | 30 |
| Montelukast Sodium | Montelukast Sodium | 155 | 35 |
| Buspirone Hcl | Buspirone Hcl | 143 | 23 |
| Ondansetron Odt | Ondansetron | 141 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 136 | 24 |
| Ventolin Hfa | Albuterol Sulfate | 135 | 23 |
| Meloxicam | Meloxicam | 127 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 123 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 122 | 18 |
| Losartan Potassium | Losartan Potassium | 117 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 116 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 115 | 21 |
| Jardiance | Empagliflozin | 108 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 106 | 16 |
| Trazodone Hcl | Trazodone Hcl | 103 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 101 | 15 |
| Metformin Hcl | Metformin Hcl | 95 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 91 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 85 | 13 |
| Potassium Chloride | Potassium Chloride | 83 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 79 | 20 |
| Eliquis | Apixaban | 79 | suppressed |
| Cefdinir | Cefdinir | 77 | 48 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 13 |
| Vascepa | Icosapent Ethyl | 73 | 12 |
| Fenofibrate | Fenofibrate | 71 | 12 |
| Mounjaro | Tirzepatide | 71 | 13 |
| Sertraline Hcl | Sertraline Hcl | 71 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 16 |
| Prednisone | Prednisone | 70 | 44 |
| Nabumetone | Nabumetone | 69 | suppressed |
| Ozempic | Semaglutide | 69 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 66 | 11 |
| Simvastatin | Simvastatin | 65 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 62 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 60 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 59 | 13 |
| Donepezil Hcl | Donepezil Hcl | 58 | 11 |
| Furosemide | Furosemide | 58 | 13 |
| Sucralfate | Sucralfate | 56 | 11 |
| Ibuprofen | Ibuprofen | 55 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 50 | suppressed |
| Amoxicillin | Amoxicillin | 49 | 38 |
| Farxiga | Dapagliflozin Propanediol | 47 | suppressed |
| Allopurinol | Allopurinol | 44 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Atenolol | Atenolol | 41 | suppressed |
| Celecoxib | Celecoxib | 41 | suppressed |
| Topiramate | Topiramate | 41 | suppressed |
| Fluconazole | Fluconazole | 37 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Methocarbamol | Methocarbamol | 35 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 33 | suppressed |
| Carvedilol | Carvedilol | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 13 |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 33 | suppressed |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Methylprednisolone | Methylprednisolone | 32 | 26 |
| Nitroglycerin | Nitroglycerin | 32 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Alprazolam | Alprazolam | 29 | suppressed |
| Azithromycin | Azithromycin | 29 | 24 |
| Bumetanide | Bumetanide | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 16 |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Kerendia | Finerenone | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 22 | 18 |
| Febuxostat | Febuxostat | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 14 |
| Valsartan | Valsartan | 16 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Roflumilast | Roflumilast | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 14 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,081.05 · 70 records | ABBVIE INC. | CAPLYTA, CREON, FARXIGA, IBSRELA, JARDIANCE, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, SPRAVATO, Tymlos, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZERBAXA | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error